Literature DB >> 26333528

Bisphosphonates for the prevention and treatment of osteoporosis.

Spyridoula Maraka1, Kurt A Kennel2.   

Abstract

Osteoporosis is a systemic skeletal disorder characterized by bone loss, which leads to impaired bone strength and an increased risk of fractures. Two million fractures are attributed to osteoporosis annually in the United States and they are associated with serious morbidity and mortality. Bisphosphonates reduce the risk of fracture by suppressing bone resorption and increasing bone strength, and they have been widely used for the prevention and treatment of osteoporosis. However, the use of these drugs for the management of osteoporosis remains a clinical challenge. There are several important considerations including appropriate patient selection, pretreatment evaluation, potential adverse effects, patient preferences, and adherence. This review will discuss the evidence informing the clinical strategy for using bisphosphonates in patients with osteoporosis and those at high risk of fracture, focusing on the benefits and risks of treatment. We will also consider issues related to the monitoring and duration of treatment. © BMJ Publishing Group Ltd 2015.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26333528     DOI: 10.1136/bmj.h3783

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  39 in total

1.  Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.

Authors:  Tomohiko Urano; Masataka Shiraki; Tatsuhiko Kuroda; Shiro Tanaka; Fumihiko Urano; Kazuhiro Uenishi; Satoshi Inoue
Journal:  J Bone Miner Metab       Date:  2017-12-13       Impact factor: 2.626

Review 2.  Using GWAS to identify novel therapeutic targets for osteoporosis.

Authors:  Olivia L Sabik; Charles R Farber
Journal:  Transl Res       Date:  2016-10-27       Impact factor: 7.012

Review 3.  Bone Mineral Disease After Kidney Transplantation.

Authors:  Josep-Vicent Torregrosa; Ana Carina Ferreira; David Cucchiari; Aníbal Ferreira
Journal:  Calcif Tissue Int       Date:  2021-03-25       Impact factor: 4.333

Review 4.  Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori
Journal:  Osteoporos Int       Date:  2016-08-25       Impact factor: 4.507

Review 5.  Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.

Authors:  K J Baatjes; J P Apffelstaedt; M J Kotze; M Conradie
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

Review 6.  Distal humerus fractures: a review of current therapy concepts.

Authors:  Steinitz Amir; Sailer Jannis; Rikli Daniel
Journal:  Curr Rev Musculoskelet Med       Date:  2016-06

7.  Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.

Authors:  E Cairoli; S Palmieri; G Goggi; L Roggero; M Arosio; I Chiodini; C Eller-Vainicher
Journal:  J Endocrinol Invest       Date:  2018-01-16       Impact factor: 4.256

Review 8.  Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer's disease.

Authors:  Angela Jeong; Kiall Francis Suazo; W Gibson Wood; Mark D Distefano; Ling Li
Journal:  Crit Rev Biochem Mol Biol       Date:  2018-06       Impact factor: 8.250

9.  Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study.

Authors:  Cesar Garriga; Michael Pazianas; Samuel Hawley; Antonella Delmestri; Daniel Prieto-Alhambra; Cyrus Cooper; Andrew Judge
Journal:  Ann N Y Acad Sci       Date:  2018-01-24       Impact factor: 5.691

10.  Effect of local application of biphosphonates on improving peri-implant osseointegration in type-2 diabetic osteoporosis.

Authors:  Xiaoqian Ding; Lan Yang; Yun Hu; Jinfeng Yu; Yu Tang; Dan Luo; Leilei Zheng
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.